Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

NCT00891878 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Gastroesophageal Junction
Esophageal Cancer

Interventions

DRUG: capecitabine
DRUG: sunitinib malate

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]